Virax Biolabs Announces Full Exercise of Pre-Funded Warrants from $5 Million Private Placement

Virax Biolabs Group Limited reported that as of April 10, 2026, all pre-funded warrants issued during a December 2025 private placement have been fully exercised. The original transaction, which closed on December 3, 2025, involved a securities purchase agreement with an accredited investor for gross proceeds of $5,000,000. In that offering, the company issued pre-funded warrants to purchase 12,500,000 ordinary shares at an exercise price of $0.0001 per share, along with preferred investment options to purchase an additional 12,500,000 ordinary shares at an exercise price of $0.40 per share. Following the full exercise of these pre-funded warrants, Virax Biolabs reported a total of 19,923,432 ordinary shares outstanding. The preferred options remain exercisable for a period of five years from the date the associated registration statement became effective. This filing serves as an update to the unregistered sale of equity securities previously disclosed in late 2025.